Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Richard Casaburi

Pulmonary Disease Torrance, CA Medical Doctor

NPI 1639149289 CMS profile 164628

21840 Normandie Ave, Ste. 700, Torrance, CA 90502

Open in the dashboard

General payments

$208,124

183 records reported · program years 2019–2025

Research payments

$2,126

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$16,563 paid to institutions, not to them · program year 2021

Through program year 2025, Richard Casaburi of Torrance, CA is reported in the CMS Open Payments database as having received $208,124 across 183 general payments and $2,126 in research payments paid to them. Separately, studies naming them as principal investigator received $16,563 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $163 2
2024 General $450 1
2023 General $10,218 5
2022 General $12,006 9
2021 General $23,226 17
2020 General $18,876 9
2020 Research $2,126 2
2019 General $143,184 140

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Richard Casaburi
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Richard Casaburi were reported at $163. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Richard Casaburi Pulmonary Disease median Middle half National median
2019 $143,184 $377 $109–$1,340 $163
2020 $18,876 $230 $56–$907 $114
2021 $23,226 $269 $68–$1,072 $132
2022 $12,006 $390 $100–$1,457 $149
2023 $10,218 $419 $114–$1,659 $160
2024 $450 $476 $123–$1,818 $164
2025 $163 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $125,559 138 payments
  2. Boehringer Ingelheim International GmbH $21,324 7 payments
  3. Genentech, Inc. $19,181 6 payments
  4. Regeneron Pharmaceuticals, Inc. $9,113 2 payments
  5. Inogen, Inc. $8,247 4 payments
  6. ViiV Healthcare Company $6,556 3 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $6,123 4 payments
  8. AstraZeneca Pharmaceuticals LP $5,706 11 payments
  9. Abbott Laboratories $5,600 3 payments
  10. Boehringer Ingelheim Taiwan Ltd. $520 1 payment
  11. Other $195 4 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $106,096 48 payments
  2. Consulting Fee $65,868 19 payments
  3. Travel and Lodging $23,056 54 payments
  4. Honoraria $6,768 3 payments
  5. Food and Beverage $3,694 56 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $2,000 1 payment
  7. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $600 1 payment
  8. Education $42 1 payment
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $83,788 91 payments
  2. Xolair $15,261 5 payments
  3. ANORO $14,531 27 payments
  4. DUPIXENT $9,113 2 payments
  5. INOGEN $6,768 3 payments
  6. FASENRA $5,100 9 payments
  7. STIOLTO $4,726 1 payment
  8. FreeStyle Libre Pro $4,000 2 payments
  9. Lucentis $3,920 1 payment
  10. Rituxan $3,920 1 payment
  11. Other $28,163 20 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. F. Hoffmann-La Roche AG $2,126 2 payments

Records

185 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record